Related Experiment Video

Updated: Jun 19, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Role of new chemotherapy agents in soft tissue sarcoma

Margaret von Mehren1

  • 1Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111-2497, USA. margaret.vonmehren@fccc.edu

Journal of the National Comprehensive Cancer Network : JNCCN
|October 13, 2009
PubMed

Insights

New targeted therapies are emerging for soft tissue sarcomas (STS), addressing the limited options in medical management. Research is evaluating novel agents like Yondelis and mTOR inhibitors for various sarcomas and GIST.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Medical management of soft tissue sarcomas (STS) is limited by the availability of effective drugs.
  • Recent advancements have introduced numerous novel oncologic agents with specific therapeutic targets.

Purpose of the Study:

  • To review the current landscape of emerging medical therapies for soft tissue sarcomas.
  • To highlight the development and evaluation of novel chemotherapeutic and targeted agents.

Main Methods:

  • Review of ongoing clinical trials and preclinical research for soft tissue sarcomas.
  • Assessment of novel agents including Yondelis, mTOR inhibitors, and growth factor receptor inhibitors.
  • Evaluation of therapeutic strategies for gastrointestinal stromal tumors (GIST), including imatinib-refractory and metastatic cases.

Main Results:

  • Gemcitabine and docetaxel show limited single-agent activity.
  • Yondelis is under investigation alone and in combination with doxorubicin.
  • Targeted agents, including mTOR inhibitors and growth factor receptor inhibitors, are being evaluated across various sarcoma subtypes.
  • Several agents are being tested in gastrointestinal stromal tumors (GIST), including in combination with imatinib for refractory or metastatic disease.

Conclusions:

  • The development of novel targeted agents for STS is rapidly advancing.
  • Understanding sarcoma biology is crucial for the effective use of these new targeted therapies.
  • Further research is needed to establish the efficacy and safety of these emerging treatments.

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...